An Ideal Way – And Ideal Time – To Invest In Biotech

2020-07-01 21_32_08-Scientist in Laboratory · Free Stock PhotoIn regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more common diseases where traditional treatments are running into limitations.” For what he sees as an ideal way to invest in biotech – and his recommendation on when to buy – CLICK HERE.

Read More

3 “Affordable Yet Compelling” Biotech Stocks With Bullish Analyst Reviews And Big Upside Potential

2020-06-27 11_57_21-Crop nurse with syringe on beige background · Free Stock PhotoClinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only are analysts bullish on but which are trading for less than $5 a share and boast upside potential of over 100%. For more, CLICK HERE.

Read More

Does Disappointment Await Investors In These COVID-19 Treatment And Vaccine Plays?

2020-06-16 18_45_22-Syringe and Pills on Blue Background · Free Stock PhotoWhen it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors are likely to end up disappointed. For more, CLICK HERE.

Read More

Top Tech Trading Under $10

2020-06-13 00_10_18-green potted plant photo – Free Plant Image on UnsplashBased on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.

Read More

This Under-The-Radar Biotech’s Only Drug Candidate Could Become “A Mega-Blockbuster”

2020-06-05 21_11_06-White Capsules on Yellow Background · Free Stock PhotoWhile buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for NASH, a severe form of non-alcoholic fatty liver disease, has posted impressive clinical trial results – and, if ultimately successful, “needs only to gobble up a small portion of the total NASH market to become a mega-blockbuster.” For more, CLICK HERE.

Read More

The Best Way To Play This – And Other – COVID-19 Biotech Stocks

2020-06-04 22_28_52-Crop chemist holding in hands molecule model · Free Stock PhotoThe biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that surge is sustainable or justified, and what the best way to play the stock (and its counterparts) may be. For more, CLICK HERE.

Read More

Should Biotech Stocks Come With A Warning Label At Current Levels?

2020-05-24 19_36_46-Woman in Gray Sweater Wearing Blue Framed Eyeglasses · Free Stock PhotoBiotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however, pointing to “two very important names” in the aforementioned ETF that “are starting to break down.” For more, CLICK HERE.

Read More

2 Biotech Penny Stocks With “Strong Buy” Ratings And “Sky-Scraping Upside Potential”

2020-05-18 22_33_16-Silver Liberty in God We Trust 1978 Coin · Free Stock PhotoAnticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.

Read More